A Phase I, Open-label Clinical Pharmacology Study to Evaluate the Effect of Tipifarnib on Cardiac Safety in Subjects With Advanced Solid Malignancies
Latest Information Update: 26 Sep 2023
At a glance
- Drugs Tipifarnib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Kura Oncology
- 19 Sep 2023 Status changed from active, no longer recruiting to discontinued.
- 03 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 15 Aug 2022 Planned End Date changed from 15 May 2022 to 15 May 2023.